Andrew Bab

Andrew Bab, Partner & Co-Chair of the Healthcare Group at Debevoise & Plimpton LLP, shares his expertise in healthcare M&A. He discusses the rapidly evolving regulatory landscape impacting private equity, highlighting state-level regulations and the implications of reverse CFIUS. Bab also delves into the complexities of Contingent Value Rights in pharma deals and how new HSR rules are reshaping auction timelines. Political scrutiny and the need for buyer-led strategies in healthcare M&A are key themes, offering vital insights for industry professionals.